Netarsudil and Low-Dose Brimonidine Ocular Residency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ophthalmological treatments for eye diseases, such as glaucoma, face challenges with patient compliance due to the frequency of administration and systemic side effects caused by rapid drug absorption, leading to reduced effectiveness and increased side effects.
Innovation Solution
A composition containing netarsudil and low-dose brimonidine, administered topically, which increases the residency time of the drug on the eye surface by reducing systemic absorption through selective vasoconstriction, thereby reducing the frequency and amount of drug needed, thus enhancing compliance and minimizing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If ophthalmological drugs are applied topically to treat eye diseases, then the drug can reach the target tissue, but the drug is rapidly removed due to tear film turnover and systemically absorbed, leading to short residency time and systemic side effects
Solution Approach 1:
The patent introduces brimonidine as an intermediary substance that mediates between the netarsudil drug and the ocular surface. Brimonidine acts as a vasoconstrictor to reduce drug clearance and as an anti-inflammatory to minimize adverse reactions, thereby extending netarsudil residency time while reducing systemic absorption and side effects
Solution Approach 2:
The patent changes the concentration parameter of brimonidine from conventional levels (0.1-0.2%) to a reduced level (0.005-0.1%), which optimizes the balance between vasoconstriction efficacy and minimization of local adverse reactions. This parameter optimization allows extended drug residency without excessive local side effects
2Reliability
If the frequency of drug administration is increased to maintain therapeutic effect, then the effectiveness of treatment is improved, but patient compliance deteriorates due to the tedious schedule
Solution Approach 1:
The patent achieves continuous therapeutic action by extending the residency time of netarsudil on the ocular surface through brimonidine-mediated vasoconstriction. This continuity allows the drug to maintain effective concentrations for longer periods, reducing the need for frequent administrations and improving patient compliance while maintaining treatment reliability
3Duration of action of moving object
If the dose of ophthalmological drugs is increased to overcome rapid clearance, then the drug residency time is improved, but systemic absorption increases leading to more side effects
Solution Approach 1:
Brimonidine serves as a mediator that addresses the clearance issue without requiring dose escalation of netarsudil. Through its vasoconstrictor action on ocular surface vessels, brimonidine reduces drug clearance rate, thereby extending residency time. Simultaneously, its anti-inflammatory properties help mitigate local adverse reactions, avoiding the need for higher netarsudil doses that would increase systemic absorption
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of netarsudil and low-dose brimonidine increases drug residency time on the eye, leading to greater effectiveness with reduced systemic side effects and improved patient compliance by allowing less frequent administration and lower drug doses.
Implementation Method 1
Brimonidine has been shown to induce vasoconstriction of the capillaries in the eye at low doses. This vasoconstriction leads to reduced redness and whitening of the sclera.
Data Source
AI summary
The present invention is related to compositions containing netarsudil and low-dose brimonidine. The present invention is further related to methods of treating ophthalmological disease by administering compositions of the present invention. The present invention is further related to methods of increasing residency time of netarsudil on the surface of an eye by co-administering low-dose brimonidine.